A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Glesatinib (Primary) ; Mocetinostat (Primary) ; Nivolumab (Primary) ; Sitravatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Mirati Therapeutics
- 09 Mar 2017 According to a Mirati Therapeutics media release, the company expects to provide initial results from this trial in the second half of 2017.
- 10 Nov 2016 Status changed from not yet recruiting to recruiting.
- 09 Nov 2016 New trial record